Smart Insulin Delivery Devices Patent Landscape Analysis Report 2026 Edition

Smart Insulin Delivery Devices Market Size, Growth Trends, and Industry Outlook

The market growth is driven by the move from manual insulin injection to automated, sensor-linked dosing, which reduces time spent outside the glucose target range. The International Diabetes Federation estimates more than 580 million adults live with diabetes, and a large share of them use insulin. FDA clearance of automated insulin delivery for type 2 diabetes in 2024 and 2025 widened the eligible population considerably.

North America leads the market because reimbursement for continuous glucose monitors and pumps is well established there. Medicare coverage of continuous glucose monitoring for insulin-treated patients raised sensor penetration, and each additional sensor user becomes a candidate for an automated pump. Europe follows, where national health systems in the United Kingdom, Germany, and the Nordic countries have funded closed-loop systems for type 1 diabetes. The growth rate also reflects a recovering base, since pump supply constraints and recalls in earlier years held back unit shipments.

Installed base data show how adoption converts into patent activity. Insulet reported more than 500,000 Omnipod users globally in 2024, and a user base of that size generates the real-world data that algorithm developers use to refine dosing logic. Connected pens add a second route, since people on multiple daily injections can adopt dose tracking at a fraction of pump cost. Both routes expand the number of devices sending data to controllers, which raises demand for interoperability and software patents.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Smart Insulin Delivery Devices Patent Filing Trends and Innovation Activity

Patent filing in smart insulin delivery devices tracks the maturity of sensor accuracy. Once continuous glucose monitors reached dependable accuracy, device makers filed heavily on algorithms that translate sensor readings into insulin commands. Pump makers file on infusion set design, occlusion detection, and cartridge handling, while pen makers file on dose-capture electronics.

Global filings exceed 15,000 patent families, with peak filing years between 2020 and 2024. Algorithm and software families grew fastest in this period, and filings for patch pump hardware followed the commercial launches of tubeless systems.

Demand for automated dosing in type 2 diabetes and paediatric care directly increases filings on adaptive algorithms, sensor interoperability, and compact pump hardware.

Scope of the Smart Insulin Delivery Devices Patent Landscape Analysis Report

The analysis covers connected insulin pens and caps, tubed insulin pumps, patch pumps, automated insulin delivery algorithms, continuous glucose monitor integration, smartphone applications, and dose decision support software. Interoperable controllers that pair with multiple pumps and sensors are included as a distinct cluster.

Patent families are grouped by technology, device format, and clinical application, and assigned to the ultimate parent entity. Granted patents, pending applications, and family size are reviewed for the period from 2015 to 2025, with attention to filings from 2020 onward.

The scope covers device manufacturers, insulin producers, sensor developers, software companies, universities, and research hospitals that hold relevant families.

Global Smart Insulin Delivery Devices Patent Landscape Analysis

Smart Insulin Delivery Devices Patent Filing Trend Analysis

Annual filings in smart insulin delivery devices grew at an estimated 9% to 11% per year between 2020 and 2024. Growth came from algorithm refinement, expansion of closed-loop systems to type 2 diabetes, and the arrival of patch pumps from multiple manufacturers.

Granted patents rose in 2024 and 2025 as applications filed during the 2020 to 2022 surge completed examination. China shows the sharpest increase in new filings, led by domestic pump and sensor developers, while United States filings remain concentrated among established device makers.

Leading Companies and Assignee Analysis in the Smart Insulin Delivery Devices Patent Landscape

Geographic Analysis of Smart Insulin Delivery Devices Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads in filing volume, supported by the largest insulin-pump market and the FDA pathway for interoperable devices. China ranks second as domestic manufacturers file on pumps, sensors, and algorithms for a large diabetes population. Europe follows through the European Patent Office, where closed-loop systems have strong public funding.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Smart Insulin Delivery Devices Technology Segmentation and Innovation Areas

The report segments patent activity by the following technology areas:

• Automated insulin dosing algorithms
• Connected pen and cap electronics
• Patch and tubed pump mechanisms
• Continuous glucose monitor integration
• Interoperable controller and app software

Among these, automated insulin dosing algorithms hold the largest share of patent families, reflecting their role as the main differentiator between competing systems.

Competitive Landscape and Emerging Trends in the Smart Insulin Delivery Devices Market

Competition in smart insulin delivery devices combines pump makers, pharmaceutical insulin producers, and sensor companies. Medtronic, Insulet, and Tandem Diabetes Care compete on closed-loop performance, while Novo Nordisk, Eli Lilly, and Sanofi position connected pens for injection users. Dexcom and Abbott supply the sensors that most automated systems depend on, which makes sensor partnerships a central part of IP strategy.

Companies are focusing on:

• Adaptive dosing algorithms with meal detection
• Closed-loop control for type 2 diabetes
• Tubeless patch pump miniaturisation
• Connected pen dose capture and reminders
• Interoperable pump and sensor controllers
• Smartphone-based bolus calculators
• Occlusion and infusion site failure detection

Emerging innovation themes include fully automated meal-time dosing without manual carbohydrate entry, dual-hormone and adjunct drug delivery, smartphone-native pump control, and pens that communicate directly with continuous glucose monitors. Interoperable controllers that pair with several pumps and sensors have drawn increased filings since 2023, supported by FDA designations for interoperable devices. Machine learning for personalised dosing is a growing cluster, especially in Europe and China.

Strategic Insights from the Smart Insulin Delivery Devices Patent Landscape

The patent field in smart insulin delivery devices is shifting from hardware claims to software and interoperability claims. Early pump patents protect mechanics, while recent families protect algorithms, data exchange, and sensor pairing. Companies with large installed bases hold an advantage, since real-world data supports continuous algorithm improvement and generates new filings.

Technology segments, device formats, and applications are mapped to assignee activity, and the report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Smart Insulin Delivery Devices Patent Landscape Analysis

The study searches patent databases including the USPTO, the European Patent Office, WIPO PATENTSCOPE, the China National Intellectual Property Administration, the Japan Patent Office, and Espacenet. Queries combine keywords with CPC classes A61M 5/172 for infusion control, A61M 5/142 for pumps, A61M 5/31 for syringes and pens, and G16H 20/17 for insulin-related health informatics.

Search results are screened for relevance, and applications are consolidated into patent families to avoid double counting. Assignee names are harmonised across subsidiaries and acquired companies, and each family is tagged by technology, device format, and application.

The market side draws on regulatory filings from the FDA and European authorities, company annual reports, clinical trial registries, and peer-reviewed literature on automated insulin delivery. Patent counts are rounded approximations and are cross-checked against product launches and clearances.

Related Reports

Smart Insulin Pens Patent Landscape Report

United States Diabetes Care Devices Market

Europe Diabetes Care Devices Market